<SEC-DOCUMENT>0001493152-25-013881.txt : 20250917
<SEC-HEADER>0001493152-25-013881.hdr.sgml : 20250917
<ACCEPTANCE-DATETIME>20250917160509
ACCESSION NUMBER:		0001493152-25-013881
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250916
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20250917
DATE AS OF CHANGE:		20250917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NanoVibronix, Inc.
		CENTRAL INDEX KEY:			0001326706
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36445
		FILM NUMBER:		251320031

	BUSINESS ADDRESS:	
		STREET 1:		969 PRUITT AVE,
		CITY:			TYLER
		STATE:			TX
		ZIP:			77569
		BUSINESS PHONE:		(914) 233-3004

	MAIL ADDRESS:	
		STREET 1:		969 PRUITT AVE,
		CITY:			TYLER
		STATE:			TX
		ZIP:			77569

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix, Inc.
		DATE OF NAME CHANGE:	20111206

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix Inc
		DATE OF NAME CHANGE:	20050510
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:NAOV="http://nanovibronix.com/20250916">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_NAOV_nanovibronix.com_20250916 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20250916_20250916 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001326706 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000004" name="dei:EntityCentralIndexKey">0001326706</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="naov-20250916.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-16</xbrli:startDate>
        <xbrli:endDate>2025-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20250916__20250916_zadFN9zujWH1"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">Date of Report (Date of earliest event reported): <span id="xdx_90C_edei--DocumentPeriodEndDate_c20250916__20250916_ze6QcXllhCVf"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September
16, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20250916__20250916_zydvLsaBazg4"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000011" name="dei:EntityRegistrantName">NanoVibronix,
Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250916__20250916_zrFvTzidWBW2"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span id="xdx_90C_edei--EntityFileNumber_c20250916__20250916_zVQRfBOu2JZh"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000013" name="dei:EntityFileNumber">001-36445</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20250916__20250916_zwEHsTIEs4wc"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000014" name="dei:EntityTaxIdentificationNumber">01-0801232</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">(State or other jurisdiction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">of incorporation)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">(Commission</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">File Number)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">(IRS Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 66%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20250916__20250916_zgi7e239XfWj"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000015" name="dei:EntityAddressAddressLine1">969 Pruitt Ave</ix:nonNumeric></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span id="xdx_902_edei--EntityAddressCityOrTown_c20250916__20250916_zrEvLkqrTqSb"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000016" name="dei:EntityAddressCityOrTown">Tyler</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20250916__20250916_znqRgyFLOb69"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span></p></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 32%"><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250916__20250916_zjFzeigujpek"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000018" name="dei:EntityAddressPostalZipCode">77569</ix:nonNumeric></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">Registrant&#8217;s telephone number, including area
code: <span id="xdx_904_edei--CityAreaCode_c20250916__20250916_zTUlAnzuyzv5"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000019" name="dei:CityAreaCode">(914)</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20250916__20250916_z4zy73HVVN8g"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000020" name="dei:LocalPhoneNumber">233-3004</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">(Former name or former address, if changed since last
report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_905_edei--WrittenCommunications_c20250916__20250916_ztpvKUrg5the"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_906_edei--SolicitingMaterial_c20250916__20250916_zw6RRLDk2MG7"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_900_edei--PreCommencementTenderOffer_c20250916__20250916_z6AVaaQDzdzk"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20250916__20250916_zNP3AoEx4zoi"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Emerging growth company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20250916__20250916_z7rFsBfl7uFc"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt:booleanfalse" id="Fact000025" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center; width: 38%"><b>Title of each class</b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 18%"><b>Trading Symbol</b></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 40%"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_90B_edei--Security12bTitle_c20250916__20250916_zBWOCWfNPEUk"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_905_edei--TradingSymbol_c20250916__20250916_zxRtP9PYJrJe"><ix:nonNumeric contextRef="AsOf2025-09-16" id="Fact000027" name="dei:TradingSymbol">NAOV</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_903_edei--SecurityExchangeName_c20250916__20250916_zSuGHX1aL2Df"><ix:nonNumeric contextRef="AsOf2025-09-16" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><b></b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">On September 16, 2025, NanoVibronix, Inc. (the &#8220;<b><i>Company</i></b>&#8221;)
entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with a single institutional investor, pursuant to
which the Company agreed to issue and sell (i) 74,114 shares (the &#8220;<b><i>Shares</i></b>&#8221;) of the Company&#8217;s common stock,
$0.001 par value per share (the &#8220;<b><i>Common Stock</i></b>&#8221;), and (ii) prefunded warrants (the &#8220;<b><i>Prefunded Warrants</i></b>&#8221;)
to purchase up to 217,090 shares of Common Stock (the &#8220;<b><i>Prefunded Warrant Shares</i></b>&#8221;) in a registered direct offering
(the &#8220;<b><i>Offering</i></b>&#8221;), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273574), a
base prospectus and prospectus supplement relating to the Offering (the &#8220;<b><i>Prospectus Supplement</i></b>&#8221;), in each case
filed with the Securities and Exchange Commission. The offering price was $7.01 per share of Common Stock and $7.009 per Prefunded Warrant,
which is the price of each share of Common Stock sold in the Offering, minus the $0.001 exercise price per Prefunded Warrant. The net
proceeds from the Offering were approximately $1.8 million, after deducting placement agent fees and estimated offering expenses payable
by the Company. The Company currently plans to use the net proceeds from the Offering primarily for general working capital purposes,
including repayment of certain outstanding indebtedness and/or redemption of certain outstanding preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The Prefunded Warrants have an initial exercise price
per share of $0.001, subject to certain adjustments. The Prefunded Warrants may be exercised at any time until exercised in full, except
that a holder (together with its affiliates) will not be entitled to exercise any portion of any Prefunded Warrant, which, upon giving
effect to such exercise would cause the aggregate number of shares of the Company&#8217;s Common Stock beneficially owned by the holder
(together with its affiliates) to exceed 4.99% (or, upon election of the holder, 9.99%) of the number of shares of Common Stock outstanding
immediately prior to or after giving effect to the exercise, subject to such holder&#8217;s rights under the Prefunded Warrants to increase
or decrease such percentage to another percentage not in excess of 9.99% of the number of shares of our common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants
upon at least 61 days&#8217; prior notice from such holder to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The Purchase Agreement contains customary representations,
warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, including for liabilities
arising under the Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;). The representations, warranties
and covenants contained in the Purchase Agreement were made only for the purposes of such agreement and as of the specific dates, were
solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The Company entered into an engagement letter (the
&#8220;<b><i>Engagement Letter</i></b>&#8221;), dated as of February 11, 2025, with Palladium Capital Group, LLC (the &#8220;<b><i>Placement
Agent</i></b>&#8221;), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company in connection
with the Offering. Pursuant to the terms of the Engagement Letter, the Company agreed to pay the Placement Agent an aggregate cash fee
equal to 8.0% of the gross proceeds received in the Offering and for certain expenses incurred by the Placement Agent in connection with
the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The foregoing description of the terms and conditions
of the Purchase Agreement and the Prefunded Warrants do not purport to be complete and are each qualified in their entirety by the full
text of the Purchase Agreement and form of Prefunded Warrant, copies of which are attached hereto as Exhibits 10.1 and 4.1, respectively,
and incorporated herein by reference. A copy of the opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale
of the Shares, the Prefunded Warrants and the Prefunded Warrant Shares is attached hereto as Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><b>Item 8.01 Other Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">On September 16, 2025, the Company issued a press
release regarding the Offering described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
  <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Prefunded Warrant, dated September 17, 2025.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Haynes and Boone, LLP.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement, dated September 17, 2025, by and between the Company and the purchaser thereto.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Haynes and Boone, LLP (included in Exhibit 5.1).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif">99.1</td>
  <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-1.htm">Press Release, dated September 16, 2025.</a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif">104</td>
  <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
  <td style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="text-transform: uppercase"><b>NanoVibronix, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: September 17, 2025 </td>
    <td>By:</td>
    <td style="border-bottom: black 1pt solid"><i>/s/ Doron Besser, M.D.</i></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name: </td>
    <td>Doron Besser, M.D.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title: </td>
    <td>Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6Lds6UHCXjinilDGGeFtdlOLWjLT+PZJvad0QQyAk53w5QkzEipa6RYbDoiqgxq5vlUOo8IyM5oTeka03KfhZ4UVbx8q4Yf2BGXkGPTML5dHfB+ddW2xSiOeRnEXJFKRM5RTKrQi+ekbmrBs0TqsWlGmgZOpZo1P8Gj/U6kmGuteQtEe2mkwKMoxH+Q1JLBPY0V09iK8WiiITwWSoQKyYbr135U+H5ktC3mLn4+xI/zv4AM3uSmA= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PREFUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NANOVIBRONIX,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares:</FONT></TD><TD STYLE="width: 5%">______
</TD><TD STYLE="text-align: right; width: 80%">Initial Exercise Date: September 17, 2025</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PREFUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is
exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;), to subscribe for and purchase from NanoVibronix, Inc. a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of the Company&rsquo;s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September 16, 2025, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share,
was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the
nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of
this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price
under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination
Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
                                            to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
                                            pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
                                            hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
                                            laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
                                            Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price
                                            of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
                                            as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such
                                            Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
                                            and is delivered within two (2) hours thereafter (including until two (2) hours after the
                                            close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof
                                            or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice
                                            of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
                                            to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD><TD STYLE="text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                            with the terms of this Warrant if such exercise were by means of a cash exercise rather than
                                            a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX Best Market
(&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by the OTC Markets,
Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the
Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market operated by the
OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period,
in each case after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case after the delivery
to the Company of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to
a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant
Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds
such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains
outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date
of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior
to 4:00 p.m. (New York City time) on the Trading Day immediately prior to the Initial Exercise Date, which may be delivered at any time
after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by
4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for
purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be [9.99/4.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise
of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the Company&rsquo;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to
sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions
of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on
the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and
which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of
such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto
and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and
the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this
Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares
and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. Other than Section 2(e) and this Section 5(l), which may not be modified, amended or waived, this Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant,
on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANOVIBRONIX,
    INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">NANOVIBRONIX,
INC.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set
forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: __________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _____________________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ______________________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 49%"><IMG SRC="ex5-1_001.jpg" ALT=""></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 49%; vertical-align: middle"><IMG SRC="ex5-1_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
17, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">969
Pruitt Avenue<BR>
Tyler, Texas 77569</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
                                            Inc.</FONT></TD>
</TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement on Form S-3 (File No. 333-273574)</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to NanoVibronix, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the
preparation and filing with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on the date hereof, pursuant
to Rule 424(b) under the Securities Act of 1933, as amended (the <B><I>&ldquo;Act&rdquo;</I></B>) of the Company&rsquo;s prospectus supplement,
dated September 16, 2025 (the &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;), forming part of the registration statement on Form
S-3 (Registration No. 333-273574), initially filed by the Company with the Commission on August 1, 2023, and declared effective on August
11, 2023 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have acted as counsel to the Company in connection with an offering of (i) 74,114 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;)
of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;) and (ii) pre-funded warrants
(the &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;) to purchase up to 217,090 shares of Common Stock (the &ldquo;<B><I>Pre-Funded Warrant
Shares</I></B>&rdquo;) that may be issued and sold under that certain Securities Purchase Agreement executed by the Company and the signatories
thereto, on September 16, 2025 (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;). The Prospectus Supplement relates to the Shares,
the Pre-Funded Warrants and the Pre-Funded Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinion set forth herein, we have examined the originals, or photostatic or certified copies, of (i) the Certificate of
Incorporation and Bylaws of the Company, each as amended and/or restated as of the date hereof, (ii) certain resolutions of the Board
of Directors of the Company related to the filing of the Registration Statement and the Prospectus Supplement, the authorization and
issuance of the Shares and related matters, (iii) the Registration Statement and all exhibits thereto, (iv) the Prospectus Supplement
and the base prospectus, dated August 11, 2023, included in the Registration Statement (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;
and together with the Prospectus Supplement, the &ldquo;<B><I>Prospectus</I></B>&rdquo;), (v) the Purchase Agreement, (vi) the specimen
Common Stock certificate, (vii) the form of Pre-Funded Warrant, (viii) a certificate executed by an officer of the Company, dated as
of the date hereof, and (ix) such other records, documents and instruments as we deemed relevant and necessary for purposes of the opinion
stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon such certificates of officers of the Company and of public officials and statements and information furnished by officers
of the Company with respect to the accuracy of material factual matters contained therein which were not independently established by
us. In such examination we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,
the conformity to original documents of all documents submitted to us as photostatic or certified copies, and the authenticity of the
originals of such copies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making the foregoing examination we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity
of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as photostatic or
certified copies, and the authenticity of the originals of such copies. As to all questions of fact material to this opinion, where such
facts have not been independently established, we have relied, to the extent we have deemed reasonably appropriate, upon representations
or certificates of officers of the Company or governmental officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
  and Boone, LLP</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
                                            Rockefeller Plaza | 26th Floor | New York, NY 10112</FONT></P>
                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T:
                         212.659.7300 | haynesboone.com</FONT></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 49%"><IMG SRC="ex5-1_001.jpg" ALT=""></TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 49%; vertical-align: middle"><IMG SRC="ex5-1_002.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 15, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not considered, and express no opinion herein as to, the laws of any state or jurisdiction other than the General Corporation Law
of the State of Delaware, as currently in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            payment and delivery in accordance with the Purchase Agreement, the Shares will be validly
                                            issued, fully paid and nonassessable.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Pre-Funded Warrants have been duly executed by the Company and delivered to and paid for
                                            by the investors pursuant to the terms of the Purchase Agreement and when the Pre-Funded
                                            Warrant Shares have been issued and delivered in accordance with the terms of the Pre-Funded
                                            Warrants, the Pre-Funded Warrant Shares will be validly issued, fully paid and non-assessable</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K to be filed with the
Commission. We further consent to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus constituting
a part of the Registration Statement. In giving this consent, we are not admitting that we are within the category of persons whose consent
is required under Section 7 of the Act or the rules and regulations of the Commission thereunder. This opinion is given as of the date
hereof and we assume no obligation to update or supplement such opinion after the date hereof to reflect any facts or circumstances that
may thereafter come to our attention or any changes that may thereafter occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">Very
truly yours,</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><I>/s/ Haynes and Boone, LLP</I></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Haynes
and Boone, LLP</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of September 16, 2025, between NanoVibronix, Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>BHCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(mm).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares and the Prefunded Warrants pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Shares and the Prefunded Warrants, in each case, have been satisfied or waived, but in no event later than
the first (1<SUP>st</SUP>) Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Haynes and Boone, LLP, with offices located at 30 Rockefeller Plaza, 26<SUP>th</SUP> Floor, New York, NY 10112.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, consultants, officers or directors of the
Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to
the Company; provided, however, that any securities issued to consultants under this clause (a) are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section 4.11(a) herein, (b) warrants to the Placement Agent in connection with the transactions
pursuant to this Agreement and any securities upon exercise of the warrants to the Placement Agent, if applicable, and/or securities
upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and
carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition
period in Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person)
which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Federal
Reserve</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(mm).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $7.01, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date, provided
that the purchase price per Prefunded Warrant shall be the Per Share Purchase Price minus $0.001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Palladium Capital Group LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prefunded
Warrant</U>&rdquo; means, collectively, the Prefunded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Prefunded Warrants shall be exercisable immediately and shall expire when exercised in full, in the
form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prefunded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Prefunded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the base prospectus filed for the Registration Statement, including all information, documents and exhibits filed with or incorporated
by reference into such prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act, including all information,
documents and exhibits filed with or incorporated by reference into such prospectus supplement, that is filed with the Commission and
delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form S-3 (File No. 333-273574) filed with the Commission, including
all information, documents and exhibits filed with or incorporated by reference into such registration statement, which registers the
issuance and sale of the Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Prefunded Warrants, and the Prefunded Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement, but excluding the Prefunded Warrant
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Shares and the Prefunded Warrants, if applicable,
purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds (excluding for the avoidance of doubt, if applicable, a Purchaser&rsquo;s
aggregate exercise price of the Prefunded Warrants, which amounts shall be paid as and when such Prefunded Warrants are exercised for
cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Prefunded Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, New York 11598 and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Purchasers, severally and not jointly, agree to purchase an aggregate of $2,041,122.95 of Shares; <U>provided</U>, <U>howeve</U>r, that,
to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates,
and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially own in
excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser
may elect, by so indicating such election prior to their issuance, to purchase Prefunded Warrants in lieu of Shares in such manner to
result in the same aggregate purchase price being paid by such Purchaser to the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, with respect to each Purchaser, at the election of such Purchaser at Closing, 9.99%) of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of the Shares on the Closing Date. In each case, the election
to receive Prefunded Warrants is solely at the option of the Purchaser. Each Purchaser&rsquo;s Subscription Amount as set forth on the
signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares (and, if applicable, a
Prefunded Warrant) as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth
in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing
shall take place remotely by electronic transmission of the Closing documentation. Unless otherwise directed by the Placement Agent,
settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo;
names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser;
upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment
therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein
to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through,
and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any
Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement
Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company),
be deemed to be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement
Shares to such Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such
Purchaser prior to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that
the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to
whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such
decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such
sale, if any. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Prefunded Warrants) delivered
on or prior to 4:00 p.m. (New York City time) on the Trading Day immediately prior to the Closing Date, which may be delivered at any
time after the time of execution of this Agreement, the Company agrees to deliver the Prefunded Warrant Shares subject to such notice(s)
by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the
Prefunded Warrants) for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable to
the Placement Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the
Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to
such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable
upon exercise of such Purchaser&rsquo;s Prefunded Warrants, if applicable), registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
if applicable, for each Purchaser of Prefunded Warrants pursuant to Section 2.1, a Prefunded Warrant registered in the name of such Purchaser
to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to
Prefunded Warrants divided by the Per Share Purchase Price minus $0.001, with an exercise price equal to $0.001, subject to adjustment
therein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount via wire transfer to the bank account of ENvue (minus, if applicable, a Purchaser&rsquo;s
aggregate exercise price of the Prefunded Warrants, which amounts shall be paid as and when such Prefunded Warrants are exercised for
cash), which shall be made available for DVP settlement with the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
such representation or warranty is as of a specific date therein in which case they shall be accurate in all material respects (or, to
the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
such representation or warranty is as of a specific date therein in which case they shall be accurate in all material respects (or, to
the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) the notice
and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Shares and
the Prefunded Warrant Shares for trading thereon in the time and manner required thereby, and (iv) such filings as are required to be
made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Prefunded Warrants, when paid for and issued in accordance with this Agreement, will constitute valid and binding
obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general
principles of equity. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement and the Prefunded Warrants. The Company has prepared and filed the Registration Statement in conformity with
the requirements of the Securities Act, which became effective on August 11, 2025, including the Prospectus, and such amendments and
supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities
Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of
the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the
Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus
Supplement with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective,
at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform
in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and
the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration
Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements
with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) calendar months
prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on in the SEC Reports. Except as set forth
in the SEC Reports, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act,
other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of
Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. Except as set
forth in the SEC Reports, no Person has any right of first refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities
and as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of
any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving
any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock
or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company
or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). Except as set forth
in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts
the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any
Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any
stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding
shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements
with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among
any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two (2) years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus
and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has
received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As
of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited
financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position
of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company equity compensation plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth in the SEC Report<U>s</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). Except as set forth in the SEC Reports, there is no Action
that (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having
valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable
to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof and as of the Closing Date, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the
Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the
disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed
periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal
control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except for compensation payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities
Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration, except as disclosed in the SEC Reports. Except as set forth in the SEC Reports, the Company has not, in the 12 months
preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect
that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth in the
SEC Reports, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with
all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company
during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes
or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. The SEC Reports <U>set</U> forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess
of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due
under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to
any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s independent registered public accounting firm is set forth in the SEC Reports. To the knowledge
and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year
ending December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage
in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the
periods that the value of the Prefunded Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging
activities (if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time
that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Prefunded Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1),
(a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo;
as defined in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 46.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Shares and Prefunded Warrant Shares.</U> The Shares shall be issued free of legends. If all or any portion of a Prefunded Warrant
is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Prefunded Warrant Shares
or if the Prefunded Warrant is exercised via cashless exercise, the Prefunded Warrant Shares issued pursuant to any such exercise shall
be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement
registering the sale or resale of the Prefunded Warrant Shares) is not effective or is not otherwise available for the sale or resale
of the Prefunded Warrant Shares, the Company shall immediately notify the holders of the Prefunded Warrants in writing that such registration
statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again
and available for the sale or resale of the Prefunded Warrant Shares (it being understood and agreed that the foregoing shall not limit
the ability of the Company to issue, or any Purchaser to sell, any of the Prefunded Warrant Shares in compliance with applicable federal
and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement)
registering the issuance or resale of the Prefunded Warrant Shares effective during the term of the Prefunded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>. Until the no Purchaser owns Securities, the Company covenants to timely file (or obtain extensions
in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof
pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including,
without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition,
effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any
of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each
Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior
consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect
to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required
by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except
(a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to
the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. Except as set forth in the Prospectus Supplement, the Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes , including repayment of certain outstanding indebtedness and/or redemption of certain
outstanding preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents, or (b) any action instituted against the Purchaser Parties in any capacity,
or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with
respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach
of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct).
If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there
is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and the position
of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party
effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations,
warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action
or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue the Shares pursuant to this Agreement and the Prefunded Warrant Shares pursuant to any exercise of the Prefunded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Shares and the Prefunded Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and the Prefunded
Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and the Prefunded Warrant Shares, and will take such other
action as is necessary to cause all of the Shares and the Prefunded Warrant Shares to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common
Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the
bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through
the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to
the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement, the filing a registration
statement on Form S-8 in connection with any employee benefit plan, or the filing of any resale registration statement or an amendment
thereto in connection with shares of Common Stock and/or shares issuable upon exercise or conversion of any Common Stock Equivalents
issued and outstanding on the date hereof or issuable pursuant to any contractual arrangement entered by the Company prior to the date
hereof..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until the one (1) year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market&rdquo; facility, whereby the
Company may issue securities at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser
by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed
to its legal and other representatives). Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be
restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent,
including, without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Capital Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock
split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the
Shares, other than a reverse stock split that is required, in the good faith determination of the Board of Directors, to maintain the
listing of the Common Stock on the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Exercise Procedures</U>. The form of Notice of Exercise included in the Prefunded Warrants set forth the totality of the procedures
required of the Purchasers in order to exercise the Prefunded Warrants. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Prefunded Warrants. Without limiting the preceding sentences, no ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
form be required in order to exercise the Prefunded Warrants. The Company shall honor exercises of the Prefunded Warrants and shall deliver
the Prefunded Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and the Prefunded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case
of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification
or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of
such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1, the covenants of the Company in Article 4 and the representations and warranties of the Purchasers in Section
3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not
for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this
Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
(including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method, such signature shall be deemed
to have been duly and validly delivered and shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Prefunded Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any
such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for
such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Prefunded Warrant
(including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms
and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NANOVIBRONIX,
                    INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron
    Besser, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to (which shall not constitute
    notice):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO NAOV SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Prefunded Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prefunded
Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)
the Closing shall occur by the first (1<SUP>st</SUP>) Trading Day following the date of this Agreement and (iii) any condition to Closing
contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed
of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead
be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate
or the like or purchase price (as applicable) to such other party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NanoVibronix
Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TYLER,
TX &ndash; September 16, 2025 &ndash; NanoVibronix, Inc. (NASDAQ: NAOV) (&ldquo;NanoVibronix&rdquo; or the &ldquo;Company&rdquo;), a
medical technology company specializing in non-invasive therapeutic systems, today announced that it has entered into a definitive agreement
with a single institutional investor for the purchase and sale of 291,204 shares of its common stock (or common stock equivalents), at
an offering price of $7.01 per share of common stock (or per common stock equivalent) in a registered direct offering priced at-the-market
under Nasdaq rules. The closing of the offering is expected to occur on or about September 17, 2025, subject to the satisfaction of customary
closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Palladium
Capital Group, LLC is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate gross proceeds to the Company from the offering are expected to be approximately $2.0 million, before deducting the placement
agent&rsquo;s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering
for general working capital purposes, including repayment of certain outstanding indebtedness and/or redemption of certain outstanding
preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities described above are being offered and sold by the Company in a registered direct offering pursuant to a &ldquo;shelf&rdquo;
registration statement on Form S-3 (File No. 333- 273574) that was filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
on August 1, 2023, as amended on August 7, 2023, which was declared effective by the SEC on August 11, 2023. The offering of the securities
is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement.
A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the
SEC and will be available on the SEC&rsquo;s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying
base prospectus, when available, may also be obtained from Palladium Capital Group, LLC at 152 West 57th Street, 24th Floor, New York,
NY 10019, by phone at 212-600-1487 or by email at jp@palladiumcapital.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of that state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NanoVibronix, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc. (NASDAQ: NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and
home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct
technology platforms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acoustic-based
therapeutic technologies, including PainShield&reg; and UroShield&reg;, which utilize proprietary low-intensity surface acoustic wave
(SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization,
and disrupt biofilms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENvue&trade;
Navigation Platform, developed and operated by ENvue Medical, with offices in Arlington Heights, Illinois, and Tel Aviv, Israel, is a
minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal
tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making
during the placement procedure. Future platform expansion may include pediatric and vascular access applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix
aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability,
and technology innovation across a range of healthcare environments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements.&rdquo; Such statements may be preceded by the words &ldquo;intends,&rdquo;
&ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo;
&ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential&rdquo;
or similar words. These forward-looking statements include, but are not limited to: statements regarding the completion of the offering,
the satisfaction of closing conditions, the use of proceeds from the offering, and future expectations and plans and prospects for the
Company. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company&rsquo;s control, and cannot be predicted or quantified;
consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of the Company&rsquo;s existing
and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure
regulatory approvals for the sale of the Company&rsquo;s products; (iv) intense competition in the medical device industry from much
larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) the Company&rsquo;s limited manufacturing
capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other
third party payers for the Company&rsquo;s products; (ix) the Company&rsquo;s ability to successfully obtain and maintain intellectual
property protection covering the Company&rsquo;s products; (x) legislative or regulatory reform impacting the healthcare system in the
U.S. or in foreign jurisdictions; (xi) the Company&rsquo;s reliance on single suppliers for certain product components, (xii) the need
to raise additional capital to meet the Company&rsquo;s future business requirements and obligations, given the fact that such capital
may not be available, or may be costly, dilutive or difficult to obtain; (xiii) the Company&rsquo;s conducting business in foreign jurisdictions
exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges,
the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv)
market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company&rsquo;s filings with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), including the
Company&rsquo;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders
are urged to read these documents free of charge on the SEC&rsquo;s web site at: http://www.sec.gov. The Company assumes no obligation
to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brett
Maas, Managing Principal, Hayden IR, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>brett@haydenir.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(646)
536-7331</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SOURCE:
NanoVibronix, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  2 -0# 2(  A$! Q$!_\0
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M\[.UB,_<KC?$?A_6/!&LQZ"\SRZ-=7D=Q;N1\KE3@'V8 X/KQ[5UWQ^ ,V@
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0_GVA_P"_8HHHK2YTW9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G "<# 2(  A$! Q$!_\0
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5+#;0KM1%_P \GWHHHKG/);OJS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>naov-20250916.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSM6bP9z5Z8aekhvWB3bckqTyQlnYmcYi8oDLzGMXwM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:NAOV="http://nanovibronix.com/20250916" elementFormDefault="qualified" targetNamespace="http://nanovibronix.com/20250916">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://nanovibronix.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20250916_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20250916_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>naov-20250916_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>naov-20250916_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="naov-20250916.xsd#Cover" roleURI="http://nanovibronix.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 16,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NanoVibronix,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0801232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">969 Pruitt Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tyler<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">233-3004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NAOV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>naov-20250916.xsd</File>
    <File>naov-20250916_lab.xml</File>
    <File>naov-20250916_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "NAOV",
   "nsuri": "http://nanovibronix.com/20250916",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "naov-20250916.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "naov-20250916_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "naov-20250916_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://nanovibronix.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-25-013881-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-013881-xbrl.zip
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M4N@N'HZ(52S&JN<&W&QPDTFMSF\]GBCK#'XHR]JTL!!)&RVKE9'EC.UW2U.
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MMY8G$R_)"WP>YQZ;REL!.DY#<8^)7IH.U :+S[""'!.=79%YL<ZJ]@FMYIB
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MK1E<4!81B;:H5%IK.6!)WG@A%\:'V_@6%U-(C8/RH(<&D]<.U$YR2Z"M%')
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M)@E]Q;9?-6<[2A(S K'K$Z"0@#/KO!PC2Z'\V!B'G^)3N.G/ECA==%:6V(R
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M.F\^6'VBM5WH^O+F9@8R;?KB*20U2."!<G/16F/WIFFZ&XX>L#A2&G?"F\^
MOURM\I3N(O4EWCVBP9CPD7$D- ;::!CU;.S?/UDLD,@GL?0Y45$UHX/<*\G?
MQ\UNF[)0LVF0C1>N!F/4@A_R#N<M;8)E(DTFUIAP[DH).=?F,H?A; ^NNF(S
MD.X".[(1Y0;OGB9=FHPRS:UT]W;U*E[O^:!JE:4; _@SJ7_J#2F!O42"3BA9
M3K(U.@UF!)].7$A7Z[UH,L2A!'\V5ZAIL,XG'O8B"=.Z0LNA>H>CHA(,X_(P
M^Q.R?"Q)/-C1X<[>JEN$?4=[(?@:0<K $ON"@R*;.4;HQX .3JO:46(YE];
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MG6C=#3T2V00T4%V:C6WCM= MPY<[)M\++Y!GTW&]U2'"4>32I?@@NE(@A\S
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M_0<6YRG#207<(),PY:":SDEUVQ(&A,Z*0E:OH7VK[1Q1</4,+B_:A$EZ(_)
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M6!^>2U*!MWS!*%A[HMUZV%&@;D7APJ0)J9;)ZPYR^"*M,[E+:66@@J9Q8@%
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M>:HZY*0S0?>3P8;R-. @93>I%8'EFC^AQ=?,&UZ2<.+1EK ,]J:,;,D\OB6
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MO!"7,NU[8^#;C21C_;9+4UF'K+L7E[5%C<X:O )%PPG.FE)DZ996VHI4::9
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M  !UJ@$ "0   &5X-"TQ+FAT;>U]>V_;V+7O_P+T'7@&IX5TP3A.,IEVDC2
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M<^#-#B\/^[TK5 W+Y,$$6;>O (GE">]!@Z18;::&J-=6=$_J;(DZ>!#%' N
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M5G DS>#%!XQ2^"4>?N7V&&W*-OEHRL%-P3'7?1',A88S82" <P5]<3!-#-"
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M*; !GL&?-!C$W6U_@[R<36_XN<$XR;HB7M?LE$+^*5"U7M QH6JYW L.<NN
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MF@+XP:Z.Y ",Q6$ZD+G5(6=_H^FB8J5([7#3,'B+8^5 -E6%!*( K2:8'L$
M/$1HGY!)@:*;<X26KT$5C#%2T8RIN!B'BADD*D6]WQNP P4.*)?L(O<G3K"5
M07\8@Q.V:X:)ZRJ-V\0O:81;0X?_,MS_<R(,CW<1AEN-,#S>11@VO!2W&F/8
M; XW=S5/R"TKD%9.10S(RZN(($<%HHQY/,:A[<3,MF00LN:6EH%HM:/IR'L%
M&<%F&:HKGB<#?FM B]G6+(O%]$(DL L [E1V2N5F1YF34Q_I]' D:>?V.C4U
MR*; 4B,4(I(5.Z.2CZ29T >X,<4(M535T0#46RH'LN#I1+!P1U)/O0L1%EW4
M75$!:CI?D#+3 O3D2409254%"H1Q;94E)2/A'DMY*R>V<M-3DR9JF?+J&87C
MWJ)QD?%NP0V+KERKTBSCGE=%GEY(P%4-IE@TA5B"(+U+JO9O>OWQM=,D1WPQ
M4_-%8)_)M"!:JGU=$IWPXL!#/5(\>%'I OSZD 785)?3#Q@ 6>4(DZ!'S:4)
M/ Z4VHDJK0?GM&P>6S75$&77\6NT*;C>;E.Q'"O3DKBFT2'PIZ(:T?%FR913
MK8FD5^I(Z^GUGDK'[3&PW)<JO,JQ-.&P%/=D@L=.]E0QPH05:\FBT$52+0I#
MS:2?F6$TE4)-1#N*"NE$_T:/[JB(ERK?\W>XHE6<CA52-#6_PG1TV=#0-1F2
M7)VK)ALD8[Z6;"I9H'PMULN7U<ONI:OAQA=U2 H)V$W,WRP_)5M,?J<M3((V
MZ"<J$ZHK.Z\3<]X!^M6%K?V>B[G2)B]77Q'.5-271!&Y<ULD03!LY21XE1B#
MH>,NP9O@ORCH5MRJ'>EOA?-0L-K^KW6"!JL-E/Q*-VH!+2M74I8\2#K&IJJL
M@3EC^?(XT;! & \HP>"OVR. )HU65_93G=)J8'.E ^D^S <*OGSGV]V290G>
MV3N,U#+1529FK?3!\<>\N,J2>)I41HOQ5;&Q9$!<JXI(,\DZ,+FEH8'%584N
M*D$& ZP(F-+(!0E9;Z1N,Z4U?152)\08T%(+*5 A$"OV+278)"&S[80LNJIV
M-+LERYJJI*R<[%P.DY]\FF.#.J'>,ZRI6)1,?'$"\T-[22%99!&)3H-\86C5
MQ#Y-[:?0,]9I6E:25'UAS93@C$2!S$?%XOE%*EWKB@'=D]_!G![;&5]NWU%L
M&8Q0UA4[K]%42:J.S"K)@U8,V32:L'(,VAETHVLS7B:V.' W\<+#((A3 9M4
MZ1J5I0+T7P%?'BIL>%;4*M4Y5<%L!'$TBZ9)Y65XMZA76 CJX@^QED6V'MFZ
M6FY9L2&:ZR7"JK [OJK9>$Z$0FR7!EKIR&5H5\E)$CIA#"G6J>2(@'40UJ=N
MT0MG(H&C^9QR,D@\2LB:G\0L$^!M;E$L86UEJJ,-*;JRJ'AAE8](>2WKI(:(
M6+AK(IB8GJ>MQ&-(><?BMF19%S8,J<+LU2 W(86ODLIJ\QT+=KS!T6&OE>XL
M:7H)%:6%\]5 HFS<0D+C,3_H4 IM])V=;KA&F.3)+DQRJV&2)[LPR>=>C/N&
M@IY*\J[I 0B\Z77JH("<%99"HQPUXE&BZC+C^(] TR!DL$N=Y^ *]RZD+08K
M4/S0RZ45'R_(=N#C$C%16&L3QT^/"E]ZF6;)U(#-*1V*]2'D\_ XPSIR>R=9
MK*Z1_DD7ZKO) =QP2%;::(6[NM @U)TR2$TS@Z:,Q5DV(_44FX"/QB!:4M"U
M?!#+;T16;/^R?E=^!%8Y?1\"W275K)2U$51?6\'I+/P=E7(*% (6NJUX8XTK
MH0ZB?<?V!#L$FI"7#)HR]F-X1F>^-MF)NO*)ZP,N1,(@K6+%L%-:Y<'&(&BH
MR0":2V!N\$6>B.F)^?':)L!5L:W!I3$H;>#:P*<FH;_9(L<)Z ANK9I?P0:H
ML)*:.][2Q:.7(81CSL$MR[5.^3UM>\392VQ%+ FA-;J2U5HKW=W0+5G61TDI
M5VVAV"@^(*P7N:\6(H651^>YR<(F&5K2B?I>6)$XTZM1==YFFR+-Q?."OY7&
M4"QVB+I&C')LG(F5.VUCV3!830/>6DWKNM^1RT0UHSN_YL:5"?G1\UA;5$I^
M.BM8:NGJU]RW7F)C98G3GG:] :)E1*ZK.>PNX)8L*Y-<>,R803N8[]P;DXCH
MM*76P%KJTZ>#;!A:J:,B<69%K "N9TR9!-F,^3_>397PHOH!IX68WWCB1LI#
M)9-(V_D*0D<"F T-4'5SS)/@@B#7U$5L1X\(81;R"]H'_,V.H+=D63.1*-1(
MT#:F?D7B04?X'/2=E$#N2+7I[GAI@'A4G-*",Y(6X)'"4C& PTA<%//L]UB'
M<]._V;^;3E;[J\W@\,A%.DI%XV10?GQ[T/YR!A#4KS5\/,W-%-W</!494"-)
M7IR,0Y%;E64GGT4ZH8H!G6,KOF#+JM)ZAO+QN@79[H)MR;)ROF _)5278!E5
M%_()YG(UD<Y13U&*";6OR%/EOZ ^L/R/7/4!59F?H393!%B'<_FIR1K8$3K^
M=2>DU+K?VT,R[O39JWF3L_\_+7^V=2W;?1(O3E\.WA/8[@)3U\A_^ZK +DK5
M\,7#TY=;O"YU,(U%7!/:^'X7VKC5T,;WN]#&O61.=Z15G)[U>[^>GI^=O'\?
M_/K3R;N3-Z_<Y L$0Z:N4!X4LFC?%LRW5:+*V::+7*&!VT6]+J[Q)"VKFE/W
MT0\44[G([5E]MZY)O#C45'+88/>&2=E,R6=:&Z_4X5F=O.T[NH86!UM_@!9>
M]YVZU(:_K?N^6[R1P/#,M([>X#:?_>V[QQOOZ4U.\>S@[,TOIX?OWIR=_A;R
M[$[/CO;L.1.3_DI.1Y/34Q))=W)2GSW%KWZ&W]_V%.^"=.88J\NG6O0_0G7@
M:[OM7]M<#Y?/5DYTM4;[)??W[O__:^6%7REWN5'IA/;$5S>K'5E\X6F=8\;$
M=M&%V+BW9BR(/?]%\T2?[IPIM^I,>;ISIGQ)ZM\:1Q!8^6=OSD^/3OJ]-Z^"
MD]].WAV=OC]I,_FW:$7K^"W6X >;+K2;6=%G[J7>@&5HYPXN0/,->5UW&._F
M-E5>SU F10D+6LSG28F@M2!@"T>Z=G"VNYV3YZGPO12PCS;_VRZ_W)=WW=XP
M&M?@T9"!!RD=0=I-25I=@K5D#(.H4KG_)7\:".L>.KR%BNX!VB2FT:-ZQP#C
MQOU>.K$ 6Z6CG& K4WY<66E$. TDIQI#JSQ?3C77_?6\9EU99N=;N*T@0\GI
M^*(M%.X":FV;%S1X/,1P*)^]H.8CA [2 (&V #T,@+80V],<]*CX-'QVCW;A
M=G%:ULY,N=E%_</VY/R3(,BC*[C%E!ROD;$^Y)1)]1[K[JOG05'>LUWX%HZ6
M<<E:D/$[478B!+TU&#9A5\$HLH!%%KE(8]AQV.KF$5(%0VLM%;]((7:*Z)I%
MG]+98M8].9&-7H\^Z1/F TQP)7>,>>HP24(O:YWEK>'KW$>Z_B*2Z E*HHR!
MW0A:C;J&-O%L:Z^1GJUG<0T^T3ZG*M.#3.VF+_,HR8JKNY5?6W/TF]'SOU;_
M,=ZSW?[>V?0)#-Z[-A9RE(<I,*$L..H)\>O!47  0@ A&L^(.=_<';G&F;#%
MZ4&W<F'N=*-O"7)WMR_W=%^VY&+>-J==Z;+[Q_O3_SD[./_PCCW1/[UY?7SR
M[I];NM(M/R@.IE,-Z6E^F7"[L1,L/H=777/!UOZSM7OSXO2EE1D/>V2W :(O
M"B[@]_<.4\X_9_^V=J<T%;7MT,U0TM;N#>4EW/+F;._N'$=U\JS?NY%-N$_[
M\CFI%C^L3+"X=_D43IA5[=<-ICQ\Y>D-!%C1IAC?22_RSM%O-+Y_\MM/IX>G
MY_W>X=TE*FRYCGC3IHA\<)7@@3\+<D37R;Y[>? >U?B?3\[@<%Z]>??S-8L;
M%5G\M:[P=LYGO=*HQS=<&X75G.>,F@3CJD %-RTQ^-52 L4!"8IE4B$U&&G9
MT@!PICE!*6&<8"\X+AC-NK)_Y0+%)7:AE8KB4V]C1'FYPV+2#J?\_M[3^8TF
MA*TJ,=U*ZH&+W._]<O#ZPTGP[N3HY/27D^.PG8:(8-!Q*K!)!B:I5IA>9:+A
MO2J)0=3%_2* =KZQ*YES*YX>_^E.[,_5J=\RF;^ZJN+&)2ZJ1HHR^[ZV)/^[
MUF/L#5RYJU_- @8<1>4)OBW3O!Y^K14;M[X7!W$,<KEJOS9_X)+<J(3]\!)!
M8[[9,]I=N-UA?LT+^*;.[^U%D0LE^SD 7R'K_,8/:W?9MOO\3F91FO'TE*(2
MW/QU\[W&7_?NMJUTY?);D 6V;<TW&VF*G_'\O"@1_#L,O(#1CF-\G31]<^-]
MO;MSTY6K;ILVGJ3.;+@F KV[$'=XY+O;\(5N@]8QUDPGN%^7X;9Q*+[B-F9_
M>1Z\X?[6SX+7457O4BA6IU#<<9+#%\7??GCXYOCO5$/^T_G/KU_^?U!+ P04
M    " "C@#%;L%"R7JD,   Q6   "0   &5X-2TQ+FAT;>U<;4\;NQ+^'BG_
MP1?=4X&4A"04N- 4"0IMT:$M@MQ6_73E[#J)V\UZ:WN!5.?'WQG;^Y+-AC9M
MPDDX5.>4)GZ;&<\\'MN/Z;SMOKLXJE8Z;\^.3^$GP3^=[GGWXNRHLVU_0NFV
M*^Z<?#C]3*Z[GR_.7F[T1:@/2:L9:=+E(Z;(>W9+KL2(AC7[18U<,\G[&] 0
MFE[.V^X%&5$YX.$AP:KI_QM'G=<?WG?SO=7[=,2#\>&/^C-U%?_.[/ ;1\_"
MGHI>=+:Q0]#W<K&2OB":W>DZ#?@ BB0?#/4BA>^<')W=#7F/ZVIEM]'J;)\<
M+4N3A8J]!C(NUR^6:<WN\<G%&7EU=G%Q>7QZ>O[^S<N-YH;Y?'UY_"KY[$;N
M">DS6?=$$-!(09_)O^Q /Z?B+??U$*LV_\!([W2ODNYOF-3<HT$2 5I$DR$1
ML+[>,*C3Z9XFK5Q_SP^@N\[YNS?D^NK5RPUVMUMO_:_9;#6^1(,-<GS1?;F!
MVG=/9[1O_Y%-XW2EJ<!,]8!Q7Y"BY"/N^P$KDZ<]+0_\=65 T\S%^KC.*LJX
MU@!]S2+-1CTFJY76?HVTF^W=-=7D(:?A2ZPT[X\7*?Y[&HJ/O"=%R.]JU<IY
MZ#765I>#O8-JY5+&7&MR?,/"F'5.$&ZZXX!):,WNJ"+[^[M[!VNK8KFWS;6R
MS:MB'=8FHV9A/<NM9C_?Y0_7O=1F-N'.K4MS+[O-1GN7AXNT_A4[3$UO%L[?
M%Z\<G<Q:^2M]/RQ:D#G^3""+-1XF ZOJ14L,VE_WG(=<R%;4 TNDM#FEVYX_
M>=-O>=.J3OL5&W"E)=5<A//ASK6FD&FR4!,1DM="CLAU?8=LON8!(^]%@^SL
M[-3;^SN[^\^W9GK5,K8KI29S7_+09]AYLV$7L$>2IJR-^!?4YTQ5*S3TR1N8
MB0 =Z'!MU?D;9F.&(R],I4^L6AG2&T:HIYE/(*_W1!PJ%@!ZDXDLQ20>-4+)
M*0OH+94,:LI(6"@AFWK(R+/ _Q:+%YV3H\[YT2LQBF@X[FR?'^&QX3-IRK9J
MA(?0,@R99QK><CTDT+A:B22+J.L.':;/ QX.T@J@@A=+KL&A3/'9G3>DX8 1
M&&C$E9HIA2LL"H(PAM5]@#4R9)*)?HU$L50Q#76U NI?Q0!MS]O/-WM;)(8)
MD$4QCCT PSYI'>SLU-!T%+S;!RL:,>SX3ABHZ<9-Q-C"EEC/V>F95%BL2"2%
MBL XL2(JCB(3,AIR1)33)^E^G[3V[':_1.G+K(OKM(OIB>@#B*.%P>HZD4;F
MU@>BBI!?K1C,SR\B1>S'^07KT" 8XPR"R+UQ7L]L/G/S!O\=QP/P>-(R2J$Y
M88I]Y@7@:#YA_3ZZ"[AI6K-::;FZ)0:8$#!=N(H6>-@-^K(C^9&"$PV4(#,1
M*N]8);A"P;7 =21Z.3CX)M\B^\]KK=9SHH;@6*K$=:Y-0=%5JI49T>J!$YM(
M$=[7&D82N:%!S,B_FXUFLT4B"%0SU QH,NX)3:? "=U_DX.\@(KU?FQ@!4!7
M C;!>EH6\JS^VE;[Y*I-]0GV GP#U%2,Q!%^;+?V:\V#9F(-T#$O5"FR%(<!
M2"BU&%B+:O"E,>DQ F$>X]R!4DH$?HJF4,.#30.%J<O!ZF4BY/% ,HL_[ Z*
M]3288(_X68%;4BVDR38THKD6-02+G\/+J0&GH()TH5$IK@)D!@ P*G%':XZ:
M$8.43$LJ\W29:_N$2RNNTCELG20N]098<"Y%!*L>X@#3N*P"]* /<NCJEEGT
M8G<P6,CLU(.C@BH ;>"CDD1#H06NM=S#CQ@1O,^AJ@?=HAP.NHSCVT(/DQ;1
M-^?,N2P,7>MD#.F9*F07-<*H-\SG*%!U&P8#=]/4X:IK,I$0&0Q*8A0JBR#&
MD=+*)X)*WZ#C*9<0&D(6AW;QX2?QX=(Z5ZE\I<[%2$G$U4P1C?40[/@]U;Q:
M09BAH<>2SFTXF<X2(494:R:54<R9]!X1((N!B3/WWXJDL++);[9F2V=W.UC<
M0TC)TKD:L2E<DNFDJ0X/O2#&.>'A?0)-X]8)#I )40 M)X@8,)0\R[ONL>F,
M+'(Z==Q,+#"%G%CF#(NM(9 @6"96%2]S85/9U<9L%"=N&A9M+:A&\VTGU@2[
MT',HGG)\W[EWNH1/^+==9^^V(->&^!#&4N#'0OHX7\*+42?K0CR$24D^*PQL
M'U4VOL5NJ',9R#^84E2.42%<;R.A6!H3#B>J%1=U%B6> '_%54IWR3#5",QQ
MA%B/'I-S2#/)S@NG0!!= [Z*XEZ *(^U8(]D'2O=9B5^AJ%@H[\?RY"KH77R
MI.]B,FI#&Y .HS6!6>I!/D4];(6@!XK1@/0AAX[AIT-!S)<1V.VJA)Y(;H<<
MM+J%#R04FJ!%(V;,"OLY7"M ?B=/M1*K!CEWAK#KFY4Z6?,HX/'(+7D#%L8P
M4@C!@2(ALMJD+<9L*45T& @LH\=)G2P$5=P;<>T6DMB$8+:,VFP+U#%[6F@.
M=9+27!\_T^D/5^,$WHOBFD.,5"3\QGJ(:?84XBNN$N9T(_HU2>C C]A X*<%
M.'; !N"&'HUHWK5-%?@>]H@*,JKI&#!Q/D<0D"7%0+4R5Q"0F3% CLTN"8?_
M%@.8)(DDPE(&4@; N$K62DBA$9M,1]4*5E5V$A"?>HR%LT$JR[XM;M<2< 1/
MPHPJ*4W7<0H3 8T!KB/(VR(0!W,4@_:2P4Y<02OC"8C!\J?!'ZH.Q V3(1H<
M-$SA_PD55ERE!R*(W$.2G$U]7.#%;"E)<FXBQHYALRS,]F_I.,3C'&*WM4*$
M$(M@^,D;VU\4V5D<%3\D)P&%?4D+6L'^EONI0KL+U:?LOOGW#+YG!/SE '.$
MI/1C3V@M1H>+95?N-.>[9KZ"+2+KLR" C=AE0+]3\A=I[T%^^SH0@*-_F:$_
M"_FU1MY_AC%:K?9$D,[L>,7MU#V\1_9VJ]W8VSUH[.\TFV""H8F,'D9$PQ.C
MG/Y+)P>O! H_*?/HE,F1(XM1AM_E5?- %2974HM5F))_0!;VKWJ=O.8L\ _)
M)1U DG3-8#\1>MB U.L)O>ST_&,R?,&G]M"G7 J0?%=( I"7NZ!W+KD4KDRY
MN1^S3#]$L=EA[BF*I82Z!:"S#98H,4H/-CQ?ZSV&>]U#$AE+YJ-QSXAW.6E#
MXP_96)>3O>=F9ANGQL[&8_._M59F <SWIS==#_*F:[W][!\0-+^GTL,^,B"+
M?Y&T= 5RY(W=9;QM6[H"9@EL/T7":JN4WN[AB;(G0L5A=</38CQW8G=X[JN@
M+"5YN*LRBH?9[H#?,2[PL-?<YN&1[Y=8<N5S2T>S-\MZ2.T5_QL6,CS[?Y4C
M;US0V_1F[]IVTD_)MH9?ZL52VD-N&-YR(A_7"3(2&OQJQ1RX3]S"V+E0<>]+
M[HKS6PS2F>-W;NY/S*U,9&\5L'K 1]P=UY.)^W9S+X"DO,E;>4-(>UAV^AHD
M>U.[E[FV];E=_.)>.FXLY,7@[[S26=K+R-;$V[Y5?$'TWVC>ET,1':>,*I\%
M'&;4(!CUD&=C"%L9.:F$4)2C<MWR($!"Z0WHYP?C^>2P+-0:Z<=(3H\HMXS4
M4(2 '$C:Z05LTOPN(_][W79R8__P[6=X5/&T807L].L66EQXM%<^@+O(4YDG
M;LI(S"9?,K?O?HR7[O?PLUW(6WX!?F$BKX^\@GFD<#WS\(8I0S--WNHDZ8!F
M<I1>O9=PR''HVR$+"^3K^:289&KGS)"CN&<*SP"Y24E_3Q)'^YA))B]"YCTH
M6,]@< H%_^[+I.R\<?V3,K/? /\ C\;=!LM<.,^-SA@PAK8=$O>+N,ANHU5X
M^I*^1GEE-PCDBL&N(GNH^Y_ZG]BBQ]R+K.S-7?8&JT$^,:0;FGU*02S)^B N
MNC!2BF()W4"OV9,XCYJL.Z$/7QBZTSO+,72<X83;G",?XR":ZUB#RM4*G7B&
M5DZ!-FS# ;^Q)"VN$CG3?!XW<-1'-I.M0G52@BH[$9"N,Q#2T)4<]PIP02B6
M=(=$<M#Y6\PQAJV:U^Y9T7XBH7G[9]67<9"RS =Q0"<(\KE7;H9C:;K#YR2Y
M^85_@E8L+)#PK9>8;:5O]#"L,[,3[8'#6N,@9RORW98S>S#H^,R) _6UFZH<
M^1F;PLP&N*-"K+;4*J0U<>G%(]@QP8PK8T6DQHVM_+8K3XQ29\!Y#NTF5YJ.
M[+M,E;T RC442$M]7)O61W@B\FAO!W:;]Q[OYVM]A%U*M:(EIC=C\'-5RUI,
MY;OS"54BP=172QBB<WZTK;:)Y55-D:K.C]9=OX0P5M2L,.2CH<6L#O#\Q,5\
M^P7Y8,_F#LD%5?KIGO[^>_K'>9->[K+;^"M_[>\ QE\5_']02P,$%     @
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M;E+[0,UK]A LF>M'U$ON2T'2A>R'AEU&&(%?+1\*-^O,84MI^0 ^!6/!+#>
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MFML'&  E2X6*GUH7FUR+* 4^K5$=3^70X,<*32J?S!51X/HZEXEOX9U;!##
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M?)KTK=$_90__MIW^"?Q_ %!+ P04    " "C@#%;V8,,4T(8   5@P  "P
M &9O<FTX+6LN:'1M[3UI=]K(LM_Y%?VX,W><$S:QV=@.]V"\Q/$:8\>9?/%I
M4 -M"TEI22S^]:^J6Q(2"!M[;.)D,N?>)*!6577M5;VP_;_QP"!#)AQNF1_^
MTG*%OP@S.Y;.S=Z'OQJMYN'A7_^KI[;[+@R#H:;S(=UW77LSGQ^-1KE1*6>)
M7EZKU6KY,8Y)JT&;X\1QQ4)!RW\].6YU^FQ L]QT7&IV6/B2P<V[Q?#Q:3BT
M+0P>&XK?!$A*^3G0\%2?OA =7,VKA[&A;N+0BAKJ!D.Y8Y6+VOI#=*@1X0OC
M16,UI!EFR+[N7!Q/A[O)XZ=#\ZZ@IM.UQ("Z($*$5,D6BMEB-0(DZ[!.#!!\
MSO6LX:-P-K(E+8 S)YSX3/%QFSHAQW4VP^X )SR -XKE8*#G9'N4VN'@+G7:
M$JS_8':PL SF)(Z63V+#.Y9GNF*23(C_,/:"(]QYT/!E;-!IX^Q+.,JDIC7D
M;6&9?)SK6 ,<62G4M&H:S891O9XB^-^VRUV#U;?SZN_4]H"YE""0+/ON\>&'
M=-,R76:ZV<N)#5SLJ$\?TBX;NWEI6WEX*Z] ;O]?-DOV.3/T3=)B[A8YI0.V
M2<;Z>(L<[LI_W!2*NS=7K3^+NP>-QCG\A5,@V>R2+Y<J-SC/F]GYW03S6QY4
M>2=\Z1EO5VHW#'0&)@#_:PR8J</_W7V#]FZZU'#8$R 5(I#V3!#$I F@!#4.
M39V-C]CDI@ >JE2LKA>>0&!U!]B\>Z/=^,:NX,-73P!1O&GUJ6#.3?%&NC8%
MPY'?/0$,"GSWW =5FB-H$>RVI4^(XTX,]B'=!;W;)%K!=LDE'\"(4S8B%]:
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MTA@N3OY69RH/)]P^\4WXYYFXM$;F@B1[;WA\]UU<?F^UG\_"ZD(63M&GZY?
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M"ALLTU,#.7+99R$_<4M?AX%^..2/]5RT9I@3*L+#,86:'#0GT8QO3MR1E"C
M0?&6#-+!TZ\PG2A?,F3 34_!\(V"C9GH<"> F8A=3<MD+K:?.F###ND*:Q!G
M^0A42FW$&7-<V#4FY \MMP$8#0-8 X+M@M81 .MUI,QLR"&4&"'2P9]=YC,6
MG(F$H$\YR<8V,QWT8'2"(3G5GD3M7A$8^!F0D@" 0 "@,)UH>P[F0!Z8 _
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M@T/='M %9>?K6J#E9FIJ^1M02P,$%     @ HX Q6]% 2'']"@  ?X8  !4
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MF):4\D)H7UA$/8TK%9.(RZGI.1O3XC 6X0^";ZR[+5O-+85_T%457QP6N0O
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MDRVFJCZNE871Q6U#K1[.O]=2X^.+K+*[T+M'SN '!-H25ST-F=.];98'T>.
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M     &5X,3 M,2YH=&U02P$"% ,4    " "C@#%;$RP&>7E!  !UJ@$ "0
M            @ &+G   97@T+3$N:'1M4$L! A0#%     @ HX Q6[!0LEZI
M#   ,5@   D              ( !*]X  &5X-2TQ+FAT;5!+ 0(4 Q0    (
M *. ,5M3I*RL:@\   D_   *              "  ?OJ  !E>#DY+3$N:'1M
M4$L! A0#%     @ HX Q6]F##%-"&   %8,   L              ( !C?H
M &9O<FTX+6LN:'1M4$L! A0#%     @ HX Q6Y;[6ITM P  [@L  !$
M         ( !^!(! &YA;W8M,C R-3 Y,38N>'-D4$L! A0#%     @ HX Q
M6]% 2'']"@  ?X8  !4              ( !5!8! &YA;W8M,C R-3 Y,39?
M;&%B+GAM;%!+ 0(4 Q0    ( *. ,5LB?ZA37@<  -Q7   5
M  "  80A 0!N86]V+3(P,C4P.3$V7W!R92YX;6Q02P4&      @ " #< 0
&%2D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="naov-20250916.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-09-16</startDate>
            <endDate>2025-09-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-16" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-16" id="Fact000004">0001326706</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-16" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-16" id="Fact000010">2025-09-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-16" id="Fact000011">NanoVibronix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-16" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-16" id="Fact000013">001-36445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-16" id="Fact000014">01-0801232</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-16" id="Fact000015">969 Pruitt Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-16" id="Fact000016">Tyler</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-16" id="Fact000017">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-16" id="Fact000018">77569</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-16" id="Fact000019">(914)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-16" id="Fact000020">233-3004</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-16" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-16" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-16" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-16" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-16" id="Fact000025">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="AsOf2025-09-16" id="Fact000026">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-16" id="Fact000027">NAOV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-16" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
